

WHAT IS CLAIMED IS:

1. Antibiotic coated porous bodies, comprising a coating made of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group consisting of the netilmicin laurate, the netilmicin dodecyl sulfate, the netilmicin myristate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the vancomycin laurate, the vancomycin dodecyl sulfate, the vancomycin myristate, the vancomycin teicoplanin, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the ciprofloxacin laurate, the ciprofloxacin myristate and the clindamycin teicoplanin, said coating being introduced into a porous system of non-metallic porous bodies and/or of metallic porous bodies.
2. Method for producing antibiotic coated porous bodies pursuant to claim 1, comprising introducing first an aqueous solution, containing at least one representative of an easily water soluble salt of at least one of netilmicin, sisomicin, clindamycin, amikacin, kanamycin, tobramycin, vancomycin, and ciprofloxacin, into the porous system of porous bodies and that after a drying phase introducing a second aqueous solution of an easily water soluble salt of lauric acid, myristic acid and/or dodecyl sulphuric acid and thereby developing a hardly water soluble antibiotic coating in the porous system of the porous body.
3. Method pursuant to claim 2, wherein the sequence of the introducing steps is reversed.
4. Method for producing antibiotic coated porous bodies pursuant to claim 1, comprising introducing a methanolic solution or an ethanolic solution of at least one representative from the group consisting of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the

ciprofloxacin myristate, the vancomycin teicoplanin and the clindamycin teicoplanin into the porous system of porous bodies and vaporizing or evaporating methanol or ethanol to form a hardly water soluble antibiotic coating.

5. Method for producing antibiotic coated porous bodies pursuant to claim 1, comprising partially dissolving and/or suspending in a dioxane-water and/or in a tetrahydrofurane-water mixture amikacin laurate, kanamycin laurate, amikacin dodecyl sulfate and/or kanamycin dodecyl sulfate to form solutions and/or suspensions and introducing these solutions and/or suspensions into the porous system of the porous bodies and vaporizing or evaporating the dioxane and water mixtures or the tetrahydrofurane and water mixtures to form an antibiotic coating that is hardly soluble in water.
6. Antibiotic coated porous bodies pursuant to claim 1, wherein the antibiotic coating is applied to porous bodies existing in the form of porous powders, porous granules, porous molded bodies and/or porous layers on compact bodies.
7. Antibiotic coated porous bodies pursuant to claim 1, wherein the coating for porous bodies, which preferably exists in the form of porous powders and/or porous granules, is produced by the addition of at least one antibiotic salt that is hardly soluble in water or in an aqueous environment from the group consisting of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the gentamicin laurate, the gentamicin myristate, the clindamycin laurate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the ciprofloxacin myristate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin dodecyl sulfate, the vancomycin teicoplanin and the clindamycin teicoplanin, particularly through a grinding process, while adding methanol, ethanol, dioxane, tetrahydrofurane and/or water or mixtures thereof.
8. Antibiotic coated porous bodies pursuant to claim 1, wherein the coating for porous bodies, which preferably exists in the form of porous powders and/or porous granules, is produced by the addition of a mixture of at least one water soluble salt of netilmicin, sisomicin, clindamycin, amikacin, kanamycin, tobramycin, vancomycin and/or

ciprofloxacin and at least one water soluble salt of lauric acid, myristic acid and/or dodecyl sulphuric acid in the presence of water or aqueous solutions, particularly through a grinding process.

9. Antibiotic coated porous bodies pursuant to claim 1, wherein the coating additionally contains easily water soluble salts of gentamicin, netilmicin, sisomicin, amikacin, kanamycin, clindamycin, tobramycin, vancomycin, ciprofloxacin and/or moxifloxacin.
10. Antibiotic coated porous bodies pursuant to claim 1, wherein the antibiotic coating is applied to resorbable porous bodies, to partially resorbable porous bodies and/or to non-resorbable, bio-compatible porous bodies.
11. Implants comprising antibiotic coated porous bodies pursuant to claim 1, which have been pressed into molded bodies with a shape of coated porous granules and/or coated porous powders.
12. Binding agents for the production of molded bodies through a pressing operation of powder mixtures, comprising antibiotic coated porous bodies pursuant to claim 1, which have been designed as antibiotically coated porous granules and/or antibiotically coated porous powders.
13. Temporary or permanent implants comprising antibiotic coated porous bodies pursuant to claim 1.
14. Antibiotic coated porous bodies pursuant to claim 1, with hardly water soluble salts from the group of the netilmicin laurate, the netilmicin myristate, the netilmicin dodecyl sulfate, the sisomicin laurate, the sisomicin myristate, the sisomicin dodecyl sulfate, the amikacin laurate, the amikacin myristate, the amikacin dodecyl sulfate, the kanamycin laurate, the kanamycin myristate, the kanamycin dodecyl sulfate, the tobramycin laurate, the tobramycin myristate, the tobramycin dodecyl sulfate, the vancomycin laurate, the vancomycin myristate, the vancomycin dodecyl sulfate, the ciprofloxacin laurate, the ciprofloxacin myristate and/or the clindamycin laurate.

15. Implants comprising antibiotic coated porous bodies pursuant to claim 14 as a controlled-release antibiotic/antibiotics preparations.